Otsuka America Pharmaceutical, Inc. and Lundbeck Cordially Invite You to Attend

MOVING BEYOND PARTIAL RESPONSE IN MDD

Adding Adjunctive REXULTI® (brexpiprazole) to an Antidepressant for Your Appropriate Adult Patients With Major Depressive Disorder (MDD)

Antidepressant

REXULTI® (brexpiprazole) + Antidepressant

REXULTI® brexpiprazole 2mg tablets

Presented by

Jason Carter, PharmD

Speaker is a paid consultant or employee of Otsuka America Pharmaceutical, Inc. and/or Lundbeck.

Program Details

Tuesday, September 19, 2023

Top Shell Grill
6080 Getwell Road
Southhaven, Mississippi
38672

The Presentation Begins at
6:00 PM Central

You Have Been Cordially Invited By
John Abadie

To Make a Reservation

Please call **901-409-4390** or email **JOHN.ABADIE@OTSUKA-US.COM**. Please refer to Meeting ID number **ORT0118421** when making your reservation.

Pre-registration to attend this program is encouraged. In accordance with updated PhRMA guidelines, no Otsuka/Lundbeck-provided alcohol will be served at this program.

The Program Will Cover

- The increasing role primary care providers (PCPs) play in treating patients with depression
- Identifying patients with MDD who may be experiencing a partial response to their antidepressant and when augmenting with an atypical antipsychotic may help
- The clinical efficacy and safety data profile of REXULTI as an adjunctive therapy for adult patients with MDD
- A hypothetical patient profile to help identify adult patients who may be appropriate for treatment with REXULTI
- An overview of the pivotal clinical data for REXULTI as a treatment option for agitation associated with dementia due to Alzheimer's diesease

The intended audience for this program is healthcare professionals (HCPs) involved in the treatment of adult patients with MDD, schizophrenia, or agitation associated with Alzheimer's dementia (AAD). This program is sponsored by Otsuka America Pharmaceutical, Inc. and Lundbeck. This invitation is nontransferable.

INDICATIONS

REXULTI is indicated for:

- Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
- Treatment of schizophrenia in adults and pediatric patients ages 13 years and older
- Treatment of agitation associated with dementia due to Alzheimer's disease

Limitations of Use: REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease.

IMPORTANT SAFETY INFORMATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD.

(continued on next page ►)

Please see accompanying FULL PRESCRIBING INFORMATION, including **BOXED WARNING**.